Humoral and cellular immunity against allogeneic antigens in patients with acute leukaemia. 1978

C Werner, and M C Correa, and M Jeannet

The humoral and cellular immunity of 12 patients with acute leukaemia (6 AML and 6 ALL) was investigated using several techniques. The study of the humoral response included the screening for allogeneic and autologous lymphocytotoxins, for cytotoxic antibodies against leukaemic blasts, Daudi cells and B lymphocytes and the detection of immune complexes. The cellular immunity was investigated by stimulation of remission lymphocytes by autologous blast cells or allogeneic lymphocytes in mixed cell cultures. Most patients have retained their humoral and cellular immune responsiveness against allogeneic antigens while there seems to be no significant response against leukaemia-associated antigens.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007519 Isoantigens Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS. Alloantigens,Alloantigen,Isoantigen
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

C Werner, and M C Correa, and M Jeannet
January 2003, Allergologia et immunopathologia,
C Werner, and M C Correa, and M Jeannet
January 1991, Terapevticheskii arkhiv,
C Werner, and M C Correa, and M Jeannet
February 2001, Voenno-meditsinskii zhurnal,
C Werner, and M C Correa, and M Jeannet
January 1983, Progress in brain research,
C Werner, and M C Correa, and M Jeannet
November 1976, Zeitschrift fur Immunitatsforschung. Immunobiology,
C Werner, and M C Correa, and M Jeannet
October 2002, Current drug targets. Immune, endocrine and metabolic disorders,
C Werner, and M C Correa, and M Jeannet
January 1969, Advances in cancer research,
C Werner, and M C Correa, and M Jeannet
January 2003, Likars'ka sprava,
C Werner, and M C Correa, and M Jeannet
January 1985, Przeglad dermatologiczny,
C Werner, and M C Correa, and M Jeannet
October 2005, Biochemical and biophysical research communications,
Copied contents to your clipboard!